Leucovorin Versus Levoleucovorin Rescue After High-dose Methotrexate in Central Nervous System Lymphoma
Anticancer Research · 2026-08 · 46 (8) · 4555-4562
DOI: 10.21873/anticanres.18311 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Anticancer Research, online erschienen am 29.07.2026. Verfasst von Toshihisa Nakashima und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National Cancer Center Japan Hospital, Tokyo, Japan; tonakash@ncc.go.jp. Hauptthemen laut MEDLINE: Leucovorin, Methotrexate, Central Nervous System Neoplasms, Lymphoma.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, National Cancer Center Japan Hospital, Tokyo, Japan; tonakash@ncc.go.jp.
- Office of Infection Control and Prevention, National Cancer Center Japan Hospital, Tokyo, Japan.
- Department of Pharmacy, National Cancer Center Japan Hospital, Tokyo, Japan.
Zitieren
APA
Nakashima, T., Imai, Y., Asano, T., & Hashimoto, H. (2026). Leucovorin Versus Levoleucovorin Rescue After High-dose Methotrexate in Central Nervous System Lymphoma. Anticancer Research, 46(8), 4555-4562. https://doi.org/10.21873/anticanres.18311
Vancouver
Nakashima T, Imai Y, Asano T, Hashimoto H. Leucovorin Versus Levoleucovorin Rescue After High-dose Methotrexate in Central Nervous System Lymphoma. Anticancer Research. 2026;46(8):4555-4562. doi:10.21873/anticanres.18311
BibTeX
@article{Nakashima2026,
author = {Nakashima, Toshihisa and Imai, Yuito and Asano, Tomohisa and Hashimoto, Hironobu},
title = {Leucovorin Versus Levoleucovorin Rescue After High-dose Methotrexate in Central Nervous System Lymphoma},
journal = {Anticancer Research},
year = {2026},
volume = {46},
number = {8},
pages = {4555--4562},
doi = {10.21873/anticanres.18311}
}
EUVIMED